The gut-brain axis, including the microbiome, leaky gut and bacterial translocation: Mechanisms and pathophysiological role in alzheimer’s disease

Current Pharmaceutical Design

Volumn 22, Issue 40, 2016, Pages 6152-6166

  Köhler, Cristiano A ^a   Maes, Michael ^b,c,d,e,f   Slyepchenko, Anastasiya ^g   Berk, Michael ^b,h   Solmi, Marco ^i,j,k   Lanctôt, Krista L ^l   Carvalho, André F ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d STATE UNIVERSITY OF LONDRINA   (Brazil)

^e MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^f Revitalis   (Netherlands)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j Local Social Sanitary Unit   (Italy)

^k Institute for Clinical Research and Education in Medicine   (Italy)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

Aging; Alzheimer s disease; Amyloid beta; Dementia; Gut; Gut brain axis; Microbiota; Neurology; Psychiatry

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; INSULIN; LIPOPOLYSACCHARIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIN;

AGING; ALZHEIMER DISEASE; BACTERIAL TRANSLOCATION; BRAIN; CLEARANCE; DISEASE EXACERBATION; GASTROINTESTINAL TRACT; GUT BRAIN AXIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN RESISTANCE; INTESTINE FLORA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; IMMUNOLOGY; INTESTINE; METABOLISM; MICROBIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BACTERIAL TRANSLOCATION; BRAIN; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES;

EID: 85007609864     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160907093807     Document Type: Review

References (286)

1. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology 2014; 76, (Part A): 27-50.
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement 2007; 3: 186-91.
3. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2006; 366: 2112-7.
4. 4. Kivipelto M, Helkala E-L, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.
5. Cherbuin N, Kim S. Dementia risk estimates associated with measures of depression: a systematic review and meta-analysis. BMJ Open 2015; 5: e008853.
6. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16: 358-72.
7. Forsythe P, Kunze WA, Bienenstock J. On communication between gut microbes and the brain. Curr Opin Gastroenterol 2012; 28 557-62.
8. Collins SM, Kassam Z, Bercik P. The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Curr Opin Microbiol 2013; 16: 240-5.
9. Douglas-Escobar M, Elliott E, Neu J. Effect of intestinal microbial ecology on the developing brain. JAMA Pediatr 2013; 167: 374-9.
10. Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 2013; 27: 73-83.
11. Cammarota G, Ianiro G, Bibbo S, Gasbarrini A. Fecal microbiota transplantation: a new old kid on the block for the management of gut microbiota-related disease. J Clin Gastroenterol 2014; 48 (Suppl 1): S80-4.
12. Bridgman SL, Kozyrskyj AL, Scott JA, Becker AB, Azad MB. Gut microbiota and allergic disease in children. Ann Allergy Asthma Immunol 2016; 116: 99-105.
13. 13. Perez-Chanona E, Trinchieri G. The role of microbiota in cancer therapy. Curr Opin Immunol 2016; 39: 75-81.
14. Bravo JA, Julio-Pieper M, Forsythe P, et al. Communication between gastrointestinal bacteria and the nervous system. Curr Opin Pharmacol 2012; 12: 667-72.
15. Udit S, Gautron L. Molecular anatomy of the gut-brain axis revealed with transgenic technologies: implications in metabolic research. Front Neurosci 2013; 7; 134.
16. Heijtz RD, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011; 108: 3047-52.
17. Aziz Q, Doré J, Emmanuel A, Guarner F, Quigley E. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motility 2013; 25: 4-15.
18. 18.Foster JA, Neufeld K-AM. Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 2013; 36: 305- 12.
19. Schwartz K, Boles BR. Microbial amyloids–functions and interactions within the host. Curr Opin Microbiol 2013; 16: 93-9.
20. Dinan TG, Cryan JF. Melancholic microbes: a link between gut microbiota and depression? Neurogastroenterol Motil 2013; 25: 713-9.
21. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011; 62: 591-9.
22. Marques C, Meireles M, Faria A, Calhau C. High-Fat Diet-Induced Dysbiosis as a Cause of Neuroinflammation. Biol Psychiatry 2016; 80(1): e3-4.
23. Lurie I, Yang YX, Haynes K, Mamtani R, Boursi B. Antibiotic exposure and the risk for depression, anxiety, or psychosis: a nested case-control study. J Clin Psychiatry 2015; 76: 1522-8.
24. Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gutintestinal permeability. J Affect Disord 2007; 99: 237-40.
25. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008; 29: 117-24.
26. Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol 2013; 48: 190-204.
27. 2727.Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014; 45: 46-62.
28. 28. Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 2013; 127: 344-54.
29. Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol 2013; 25: 488-795.
30. Althani A, Marei HE, Hamdi WS, et al. Human microbiome and its association with health and diseases. J Cell Physiol 2016; 237(8): 1688-94.
31. 31.Bravo JA, Julio-Pieper M, Forsythe P, et al. Communication between gastrointestinal bacteria and the nervous system. Curr Opin Pharmacol 2012; 12: 667-72.
32. 32.De Palma G, Collins SM, Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes 2014; 5: 419- 29.
33. Catanzaro R, Anzalone M, Calabrese F, et al. The gut microbiota and its correlations with the central nervous system disorders. Panminerva Med 2015; 57: 127-43.
34. Borre YE, Moloney RD, Clarke G, Dinan TG, Cryan JF. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. In: Mark L, John FC, Eds. Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. USA: Springer 2014; pp. 373-403.
35. Bekkering P, Jafri I, van Overveld FJ, Rijkers GT. The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes. Expert Rev Clin Immunol 2013; 9: 1031-41.
36. Bhattacharjee S, Lukiw WJ. Alzheimer’s disease and the microbiome. Front Cell Neurosci 2013; 7: 153.
37. 37.Alam MZ, Alam Q, Kamal MA, Abuzenadah AM, Haque A. A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer’s disease pathogenicity: an update. CNS Neurol Disord Drug Targets 2014; 13: 383-90.
38. Friedland RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimer’s Dis 2015; 45: 349- 62.
39. 39. Shoemark DK, Allen SJ. The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer’s disease. J Alzheimers Dis 2015; 43: 725-38.
40. Kumar A, Singh A. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 2015; 67: 195- 203.
41. 41.Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
42. Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane- bound protease. Proc Natl Acad Sci USA 1992; 89: 6075-9.
43. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer’s disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012; 73: 504-17.
44. Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell 2007; 131: 215-21.
45. Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem 2009; 110: 1129-34.
46. 46.O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 2011; 34: 185-204.
47. Kurz A, Perneczky R. Novel insights for the treatment of Alzheimer’s disease. Prog in Neuro-Psychopharmacol Biol Psychiatry 2011; 35: 373-9.
48. Kumar A, Dogra S. Neuropathology and therapeutic management of Alzheimer’s disease--An update. Drugs Future 2008; 33 433-46.
49. Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer’s disease and tauopathies. Curr Alzheimer Res 2013; 10: 217-28.
50. Dal Prà I, Chiarini A, Gui L, et al. Do astrocytes collaborate with neurons in spreading the “infectious” Aβ and Tau drivers of Alzheimer’s disease? Neuroscientist 2015; 21: 9-29.
51. 51.Roth AD, Ramírez G, Alarcón R, Von Bernhardi R. Oligodendrocytes damage in Alzheimer’s disease: beta amyloid toxicity and inflammation. Biol Res 2005; 38: 381-387.
52. 52. Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer’s disease. J Neurol Sci 2013; 333: 50- 4.
53. Yasojima K, McGeer E, McGeer P. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 2001; 919: 115-21.
54. Braak H, Del Tredici K. Alzheimer’s pathogenesis: is there neuronto- neuron propagation? Acta Neuropathol 2011; 121: 589-95.
55. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084- 9.
56. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913-7.
57. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 1975; 72: 1858-62.
58. 58.Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm (Vienna) 2005; 112: 813-38.
59. Pevalova M, Filipcik P, Novak M, Avila J, Iqbal K. Posttranslational modifications of tau protein. Bratisl Lek Listy 2006; 107: 346-53.
60. 60.Hanger DP, Byers HL, Wray S, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 2007; 282: 23645-54.
61. Ksiezak-Reding H, Liu WK, Yen SH. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res 1992; 597: 209-19.
62. 62.Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 1993; 268: 24374-84.
63. Kenessey A, Yen SH. The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. Brain Res 1993; 629: 40-6.
64. 64.Ferrer I, Gomez-Isla T, Puig B, et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr Alzheimer Res 2005; 2: 3-18.
65. 65. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007; 6: 464-79.
66. Goedert M, Jakes R, Qi Z, Wang JH, Cohen P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMPdependent protein kinase. J Neurochem 1995; 65: 2804-7.
67. 67.Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 1996; 17: 1201-7.
68. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer’s disease. J Biol Chem 2000; 275: 5535-44.
69. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 2016; 12: 15-27.
70. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11: 200.
71. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol 2014; 14: 463-77.
72. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-15.
73. Antonell A, Mansilla A, Rami L, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. J Alzheimers Dis 2014; 42: 901-8.
74. Zhang B, Gaiteri C, Bodea L-G, et al Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 2013; 153: 707-20.
75. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16: 358-72.
76. 76.Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 2011; 14: 1227-35.
77. Fassbender K, Walter S, Kuhl S, et al. The LPS receptor (CD14) links innate immunity with Alzheimer’s disease. FASEB J 2004; 18: 203-5.
78. Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar β-amyloid through a β1 integrin-dependent mechanism. J Neurosci 2004; 24: 9838-46.
79. 79.Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11: 155-61.
80. 80.El Khoury JB, Moore KJ, Means TK, et al. CD36 mediates the innate host response to β-amyloid. J Exp Med 2003; 197: 1657-66.
81. 81.Fillit H, Ding W, Buee L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci Lett 1991; 129: 318- 20.
82. 82.Griffin W, Stanley L, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7611-5.
83. 83.Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer’s disease amyloid β-protein via a scavenger receptor. Neuron 1996; 17: 553-65.
84. Lee CD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Trans 2010; 117: 949-60.
85. Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PloS One 2013; 8: e60921.
86. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci 2008; 28: 8354-60.
87. Lucin KM, O’Brien CE, Bieri G, et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s disease. Neuron 2013; 79: 873-86.
88. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science 2010; 330: 1774-4.
89. vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med 2012; 18: 1812-9.
90. Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learningdependent synapse formation through brain-derived neurotrophic factor. Cell 2013; 155: 1596-609.
91. Miller KR, Streit WJ. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol 2007; 3: 245-53.
92. 92.Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia 2004; 45: 208-12.
93. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimerlike disease. Nat Med 2007; 13: 432-8.
94. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of β-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2009; 106: 1261-6.
95. Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 2014; 81: 229-48.
96. 96.Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010; 119: 7-35.
97. Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 2013; 239: 133- 8.
98. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ. Agedependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission. Mol Neurodegener 2011; 6: 55.
99. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia 2010; 58: 831-8.
100. Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang H-Y. Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003; 971: 197- 209.
101. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat Med 2003; 9: 453- 7.
102. Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat Med 2004; 10: 719-26.
103. 103.Terwel D, Steffensen KR, Verghese PB, et al. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J Neurosci 2011; 31: 7049-59.
104. Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia 2011; 59: 1643-57.
105. 105.Saido T, Leissring MA. Proteolytic degradation of amyloid β- protein. Cold Spring Harbor Perspect Med 2012; 2: a006379.
106. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. Cold Spring Harbor Perspect Med 2012; 2: a006346.
107. Mitew S, Kirkcaldie MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC. Focal demyelination in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol 2010; 119: 567-77.
108. 108.Hosokawa M, Klegeris A, Maguire J, McGeer PL. Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia 2003; 42: 417-23.
109. Yamada T, Akiyama H, McGeer P. Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. Neurosci Lett 1990; 112: 161-6.
110. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 2010; 68: 930-41.
111. Schrag M, Mueller C, Zabel M, et al. Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a metaanalysis. Neurobiol Dis 2013; 59: 100-10.
112. Saleem M, Herrmann N, Swardfager W, Eisen R, Lanctot KL. Inflammatory markers in mild cognitive impairment: a metaanalysis. J Alzheimers Dis 2015; 47: 669-79.
113. Bonaccorso S, Lin A, Song C, et al. Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milano) 1998; 10: 316-23.
114. Morris G, Carvalho AF, Anderson G, Galecki P, Maes M. The many neuroprogressive actions of tryptophan catabolites (TRYCATs) that may be associated with the pathophysiology of neuroimmune disorders. Curr Pharm Des 2016; 22: 963-77.
115. Duleu S, Mangas A, Sevin F, Veyret B, Bessede A, Geffard M. Circulating antibodies to IDO/THO pathway metabolites in Alzheimer’s disease. Int J Alzheimers Dis 2010; 2010.
116. Kita T, Morrison PF, Heyes MP, Markey SP. Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain. J Neurochem 2002; 82: 258-68.
117. 117.Onodera T, Jang MH, Guo Z, et al. Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions. J Immunol 2009; 183: 5608-14.
118. Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 2009; 15: 1391-6.
119. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73: 768-74.
120. Kyrkanides S, Tallents RH, Miller J, et al. Osteoarthritis accelerates and exacerbates Alzheimer’s disease pathology in mice. J Neuroinflammation 2011; 8: 112.
121. 121.Gisondi P, Sala F, Alessandrini F, et al. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology 2014; 228: 78-85.
122. Abuabara K, Azfar R, Shin D, Neimann A, Troxel A, Gelfand J. Cause‐specific mortality in patients with severe psoriasis: a population‐ based cohort study in the UK. Br J Dermatol 2010; 163: 586-92.
123. Thaler JP, Yi CX, Schur EA, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012; 122: 153.
124. 124.Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010; 107: 7036-41.
125. Mayeux R, Ottman R, Tang MX, et al. Genetic susceptibility and head injury as risk factors for Alzheimer’s disease among community‐ dwelling elderly persons and their first‐degree relatives. Ann Neurol 1993; 33: 494-501.
126. Heneka MT, Ramanathan M, Jacobs AH, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006; 26: 1343-54.
127. Bu XL, Yao XQ, Jiao SS, et al. A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol 2015; 22(12): 1519-25.
128. Minihane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr 2015; 114: 999-1012.
129. Shen N, Clemente JC. Engineering the microbiome: A novel approach to immunotherapy for allergic and immune diseases. Curr Allergy Asthma Rep 2015; 15: 39.
130. Palm NW, de Zoete MR, Flavell RA. Immune-microbiota interactions in health and disease. Clin Immunol 2015; 159: 122-7.
131. Stilling RM, Dinan TG, Cryan JF. Microbial genes, brain & behaviour– epigenetic regulation of the gut–brain axis. Genes, Brain Behavior 2014; 13: 69-86.
132. 132.Burokas A, Moloney RD, Dinan TG, Cryan JF. Chapter onemicrobiota regulation of the mammalian gut–brain axis. Adv Appl Microbiol 2015; 91: 1-62.
133. Shoemark DK, Allen SJ. The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer’s disease. J Alzheimer’s Dis 2015; 43(3): 725-38.
134. Claesson MJ, Cusack S, O’Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108: 4586-91.
135. 135.Hopkins M, Sharp R, Macfarlane G. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 2001; 48: 198-205.
136. Hopkins M, Macfarlane G. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 2002; 51: 448-54.
137. Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and nonantibiotic- treated elderly subjects. Appl Environ Microbiol 2004; 70: 6113-22.
138. Woodmansey E. Intestinal bacteria and ageing. J Appl Microbiol 2007; 102: 1178-86.
139. Mariat D, Firmesse O, Levenez F, et al. The Firmicutes/ Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009; 9: 123.
140. Zwielehner J, Liszt K, Handschur M, Lassl C, Lapin A, Haslberger AG. Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. Exp Gerontol 2009; 44: 440-6.
141. Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 2014; 146: 1449-58.
142. 142.Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488: 178-84.
143. 143.Ostan R, Bucci L, Capri M, et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation 2008; 15: 224-40.
144. Franceschi C, Bonafè M, Valensin S, et al. Inflamm‐aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-54.
145. Guigoz Y, Doré J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metabol Care 2008; 11: 13-20.
146. Bäuerl C, Llopis M, Antolín M, et al. Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa. Genes Nutr 2013; 8: 165-80.
147. Heuvelin E, Lebreton C, Grangette C, Pot B, Cerf-Bensussan N, Heyman M. Mechanisms involved in alleviation of intestinal inflammation by Bifidobacterium breve soluble factors. PLoS One 2009; 4: e5184.
148. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-6.
149. van Baarlen P, Troost F, van der Meer C, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci USA 2011; 108: 4562-9.
150. 150.Ouwehand AC, Bergsma N, Parhiala R, et al. Bifidobacterium microbiota and parameters of immune function in elderly subjects. FEMS Immunol Med Microbiol 2008; 53: 18-25.
151. 151.Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5: e10667.
152. Borre YE, O’Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med 2014; 20: 509-18.
153. Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 2011; 141: 769-76.
154. 154.Tran L, Greenwood-Van Meerveld B. Age-associated remodeling of the intestinal epithelial barrier. J Gerontol Ser A: Biol Sci Med Sci 2013; 68: 1045-56.
155. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-81.
156. Marques F, Sousa JC, Sousa N, Palha JA. Blood–brain-barriers in aging and in Alzheimer’s. Mol Neurodegenes 2013; 8: 38.
157. Brenner SR. Blue-green algae or cyanobacteria in the intestinal micro-flora may produce neurotoxins such as Beta-N Methylamino- L-Alanine (BMAA) which may be related to development of amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson-Dementia-Complex in humans and Equine Motor Neuron Disease in horses. Med Hypotheses 2013; 80: 103.
158. Lucas K, Morris G, Anderson G, Maes M. The toll-like receptor radical cycle pathway: a new drug target in immune-related chronic fatigue. CNS Neurol Disord Drug Targets 2015; 14: 838-54.
159. Hanke ML, Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond) 2011; 121: 367-87.
160. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010; 58: 253-63.
161. Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract 2010; 2010: 240365.
162. Hansen MK, Nguyen KT, Goehler LE, et al. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1beta protein in rats. Auton Neurosci 2000; 85: 119-26.
163. 163.Dockray GJ. Enteroendocrine cell signalling via the vagus nerve. Curr Opin Pharmacol 2013; 13: 954-8.
164. Garcia-Oscos F, Pena D, Housini M, et al. Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex. Brain Behav Immun 2015; 43: 149-58.
165. Garcia-Oscos F, Pena D, Housini M, et al. Activation of the antiinflammatory reflex blocks lipopolysaccharide-induced decrease in synaptic inhibition in the temporal cortex of the rat. J Neurosci Res 2015; 93: 859-65.
166. 166.Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173: 3916-24.
167. 167.Frank S, Copanaki E, Burbach GJ, Muller UC, Deller T. Differential regulation of toll-like receptor mRNAs in amyloid plaqueassociated brain tissue of aged APP23 transgenic mice. Neurosci Lett 2009; 453: 41-4.
168. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13: 460-9.
169. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412: 346-51.
170. Shim JH, Xiao C, Paschal AE, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005; 19: 2668-81.
171. 171.Sato S, Sugiyama M, Yamamoto M, et al. Toll/IL-1 receptor domain- containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFNregulatory factor-3, in the Toll-like receptor signaling. J Immunol 2003; 171: 4304-10.
172. Yamamoto M, Sato S, Mori K, et al. Cutting edge: a novel Toll/IL- 1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002; 169: 6668-72.
173. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003; 300: 1148-51.
174. 174.Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001; 50: 443-51.
175. Mukherjee S, Karmakar S, Babu SS. TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review. Brazil J Infect Dis 2016; 20(2): 193-204.
176. Raj DD, Moser J, van der Pol SM, et al. Enhanced microglial proinflammatory response to lipopolysaccharide correlates with brain infiltration and blood-brain barrier dysregulation in a mouse model of telomere shortening. Aging Cell 2015; 14: 1003-13
177. Lien E, Means TK, Heine H, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497-504.
178. 178.Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J Neuroinflamm 2014; 11: 48-48.
179. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 2010; 87: 989-99.
180. Liu Y, Walter S, Stagi M, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer’s amyloid peptide. Brain 2005; 128: 1778-89.
181. Potgieter M, Bester J, Kell DB, Pretorius E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev 2015; 39: 567-91.
182. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 2015; 9: 392.
183. 183.Choi SH, Aid S, Kim HW, Jackson SH, Bosetti F. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem 2012; 120: 292-301.
184. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006; 129: 3006-19.
185. Lim J-E, Kou J, Song M, et al. MyD88 deficiency ameliorates β- amyloidosis in an animal model of Alzheimer’s disease. Am J Pathol 2011; 179: 1095-103.
186. Michaud JP, Halle M, Lampron A, et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology. Proc Natl Acad Sci USA 2013; 110: 1941-6.
187. Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J Neurosci 2008; 28 5784-93.
188. Liu S, Liu Y, Hao W, et al. TLR2 is a primary receptor for Alzheimer’s amyloid beta peptide to trigger neuroinflammatory activation. J Immunol 2012; 188: 1098-107.
189. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}- stimulated microglial activation. J Neurosci 2009; 29: 11982-92.
190. Syed AK, Boles BR. Fold modulating function: bacterial toxins to functional amyloids Front Microbiol 2014; 5: 401.
191. Lei YMK, Nair L, Alegre M-L. The interplay between the intestinal microbiota and the immune system. Clin Res Hepatol Gastroenterol 2015; 39: 9-19.
192. Rhee SH. Lipopolysaccharide: basic biochemistry, intracellular signaling, and physiological impacts in the gut. Intestinal Res 2014; 12: 90-5.
193. Alonso R, Pisa D, Rábano A, Carrasco L. Alzheimer’s disease and disseminated mycoses. Eur J Clin Microbiol Infect Dis 2014; 33: 1125-32.
194. Alonso R, Pisa D, Marina AI, Morato E, Rábano A, Carrasco L. Fungal infection in patients with Alzheimer’s disease. J Alzheimer’s Dis 2013; 41: 301-11.
195. Barnhart MM, Chapman MR. Curli biogenesis and function. Ann Rev Microbiol 2006; 60: 131-47.
196. Rapsinski GJ, Newman TN, Oppong GO, van Putten JPM, Tükel Ç. CD14 protein acts as an adaptor molecule for the immune recognition of salmonella curli fibers. J Biol Chem 2013; 288: 14178- 88.
197. 197.Asti A, Gioglio L. Can a bacterial endotoxin be a key factor in the kinetics of amyloid fibril formation? J Alzheimer’s Dis 2013; 39: 169-79.
198. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. DNA Res 2009; 16: 1-12.
199. Oakley R, Tharakan B. Vascular hyperpermeability and aging. Aging Dis 2014; 5: 114.
200. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8: 967-74.
201. 201.Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
202. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 2007; 448: 484-7.
203. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 201: 233-240.
204. Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 2006 441: 231-4.
205. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448: 480-3.
206. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006 24: 179-89.
207. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
208. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria Cell 2009; 139: 485-98.
209. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011 332: 974-7.
210. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-) evolutionary perspective. Nat Rev Immunol 2009 9 883-9.
211. Raftery LA, Sutherland DJ. TGF-β family signal transduction in Drosophila development: from Mad to Smads Dev Biol 1999; 210: 251-68.
212. 212.Ouyang W, Kolls JK, Zheng Y The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-67.
213. 213.Dong C. Genetic controls of Th17 cell differentiation and plasticity. Exp Mol Med 2011 43: 1-6.
214. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2013; 2: e60.
215. 215.Fantini MC, Rizzo A, Fina D, et al. IL‐21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007; 37: 3155-63.
216. Samson M, Audia S, Janikashvili N, et al. Brief Report: Inhibition of interleukin‐6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2499- 503.
217. Chen J-M, Jiang G-X, Li Q-W, Zhou Z-M, Cheng Q. Increased serum levels of interleukin-18,-23 and-17 in chinese patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2014; 38: 321-9.
218. 218.Zhang J, Ke K-F, Liu Z, Qiu Y-H, Peng Y-P. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of Aβ 1-42- induced Alzheimer’s disease model rats. PLoS One 2013; 8 e75786.
219. 219.Tian A, Ma H, Zhang R, et al. Interleukin17A promotes postoperative cognitive dysfunction by triggering β-amyloid accumulation via the transforming growth factor-β (TGFβ)/Smad signaling pathway. PloS One 2015; 10: e0141596.
220. 220.Tang SC, Lathia JD, Selvaraj PK, et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 2008; 213: 114-21.
221. 221.Walter S, Letiembre M, Liu Y, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 2007; 20: 947-56.
222. 222.Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 2008; 104: 524-33.
223. 223. Bate C, Kempster S, Williams A. Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells. Neuropharmacology 2006; 50: 229-37.
224. Bate C, Veerhuis R, Eikelenboom P, Williams A. Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport 2004; 15: 1427-30.
225. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J 2016; 92: 63-9.
226. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease Diabetes 2004; 53: 474-81.
227. 227.Talbot K, Wang H-Y, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316.
228. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers. J Clin Invest 2012; 122: 1339.
229. Suzanne M, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimer’s Dis 2005; 7: 45-61.
230. Suzanne M, Wands JR. Alzheimer’s disease is type 3 diabetes— evidence reviewed. J Diabetes Sci Technol 2008; 2: 1101-13.
231. 231.Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005 102: 11070-5.
232. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-3.
233. 233.Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31.
234. 234.Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010; 18: 190-5.
235. 235.Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279-88.
236. Guo S, Al-Sadi R, Said HM, Ma TY. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol 2013; 182: 375-87.
237. 237. Teixeira TF, Collado MC, Ferreira CL, Bressan J, Peluzio Mdo C. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res 2012; 32: 637-47.
238. 238.Moreno-Navarrete JM, Sabater M, Ortega F, Ricart W, Fernandez- Real JM. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One 2012; 7: e37160.
239. de La Serre CB, Ellis CL, et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010 299 G440-8.
240. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2070; 56: 1761-72.
241. 241.Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr Diab Rep 2004; 4: 237-46.
242. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-92.
243. 243.Gasparini L, Gouras GK, Wang R, et al. Stimulation of betaamyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561-70.
244. 244. Arab L, Sadeghi R, Walker D, Lue L, Sabbagh M. Consequences of aberrant insulin regulation in the brain: can treating diabetes be effective for Alzheimer’s disease. Curr Neuropharmacol 2011; 9: 693.
245. 245.Lue L-F, Andrade C, Sabbagh M, Walker D. Is there inflammatory synergy in type II diabetes mellitus and Alzheimer’s Disease? Int J Alzheimer’s Dis 2012; 2012: 918680.
246. 246.Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 2916-24.
247. 247.Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-103.
248. 248.Backhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab 2011; 58 (Suppl 2): 44-52.
249. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34: 39-58.
250. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germfree mice. Proc Natl Acad Sci USA 2007; 104: 979-84.
251. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Krakoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65.
252. 252.Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-9.
253. Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care 2010; 13: 715-21.
254. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 2001; 276: 44641-6.
255. Bocker U, Yezerskyy O, Feick P, et al. Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression. Int J Colorectal Dis 2003; 18: 25-32.
256. Chakravortty D, Koide N, Kato Y, et al. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 2000; 6: 243-7.
257. 257.Luhrs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the shortchain fatty acid butyrate. Int J Colorectal Dis 2001 16: 195-201.
258. 258.Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 2013; 14: 401-6.
259. Zhang F, Kang Z, Li W, Xiao Z, Zhou X. Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimer’s disease. J Clin Neurosci 2012; 19: 946- 49.
260. Michalski B, Corrada MM, Kawas CH, Fahnestock M. Brainderived neurotrophic factor and TrkB expression in the “oldestold,” the 90+ Study: correlation with cognitive status and levels of soluble amyloid-beta. Neurobiol Aging 2015; 36: 3130-9.
261. Lakhan SE, Caro M, Hadzimichalis N. NMDA receptor activity in neuropsychiatric disorders. Front Psychiatry 2013; 4: 52.
262. Wang D, Jacobs SA, Tsien JZ. Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline. Expert Opin Ther Targets 2014; 18: 1121-30.
263. Fan X, Jin WY, Wang YT. The NMDA receptor complex: a multifunctional machine at the glutamatergic synapse. Front Cell Neurosci 2014; 8: 160.
264. 264.Zadori D, Veres G, Szalardy L, Klivenyi P, Toldi J, Vecsei L. Glutamatergic dysfunctioning in Alzheimer’s disease and related therapeutic targets. J Alzheimers Dis 2014; 42 (Suppl 3): S177-87.
265. 265.Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Abeta-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener 2014; 9: 48.
266. Li W, Dowd SE, Scurlock B, Acosta-Martinez V, Lyte M. Memory and learning behavior in mice is temporally associated with dietinduced alterations in gut bacteria. Physiol Behav 2009; 96: 557- 67.
267. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes 2011; 2: 256-61.
268. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-12.
269. 269.Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599-609, 609.e1-3.
270. 270.O’Sullivan E, Barrett E, Grenham S, et al. BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? Benef Microbes 2011; 2: 199-207.
271. 271.Savignac HM, Corona G, Mills H, et al. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochem Int 2013; 63: 756-64.
272. 272.Matsumoto T, Rauskolb S, Polack M, et al. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci 2008; 11(2): 131-3.
273. 273.Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306: 487-491.
274. Kim JA, Tran ND, Li Z, Yang F, Zhou W, Fisher MJ. Brain endothelial hemostasis regulation by pericytes. J Cereb Blood Flow Metab 2006; 26: 209-17.
275. 275.Arisi I, D’Onofrio M, Brandi R, et al. Time dynamics of protein complexes in the AD11 transgenic mouse model for Alzheimer’s disease like pathology. BMC Neurosci 2015; 16: 28.
276. 276.Capsoni S, Carucci NM, Cattaneo A. Pathogen free conditions slow the onset of neurodegeneration in a mouse model of nerve growth factor deprivation. J Alzheimers Dis 2012; 31: 1-6.
277. Brenner SR. Blue-green algae or cyanobacteria in the intestinal micro-flora may produce neurotoxins such as Beta-NMethylamino- L-Alanine (BMAA) which may be related to development of amyotrophic lateral sclerosis, Alzheimer’s disease and parkinson-dementia-complex in humans and equine motor neuron disease in horses. Med Hypotheses 2013; 80: 103.
278. Banack SA, Caller TA, Stommel EW. The cyanobacteria derived toxin Beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis. Toxins (Basel) 2010; 2: 2837-50.
279. Chiu AS, Gehringer MM, Braidy N, Guillemin GJ, Welch JH, Neilan BA. Excitotoxic potential of the cyanotoxin beta-methylamino- L-alanine (BMAA) in primary human neurons. Toxicon 2012; 60: 1159-65.
280. Jaeger LB, Dohgu S, Sultana R, et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer’s disease. Brain Behav Immun 2009; 23: 507-17.
281. Erickson MA, Hartvigson PE, Morofuji Y, et al. Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflamm 2012; 9: 150.
282. 282.Hashimoto S, Amaya F, Oh-Hashi K, Kiuchi K, Hashimoto S. Expression of neutral endopeptidase activity during clinical and experimental acute lung injury. Respir Res 2010; 11: 164.
283. Michielan A, D’Inca R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediat Inflamm 2015; 2015: 628157.
284. Dash S, Clarke G, Berk M, Jacka FN. The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry 2015; 28: 1-6.
285. Berendsen A, Santoro A, Pini E, et al. A parallel randomized trial on the effect of a healthful diet on inflammageing and its consequences in European elderly people: design of the NU-AGE dietary intervention study. Mech Ageing Dev 2013; 134: 523-30.
286. Santoro A, Pini E, Scurti M, et al. Combating inflammaging through a Mediterranean whole diet approach: the NU-AGE project’s conceptual framework and design. Mech Ageing Dev 2014; 136-137: 3-13.